Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad

J Interv Card Electrophysiol. 2019 Nov;56(2):173-182. doi: 10.1007/s10840-019-00607-x. Epub 2019 Aug 16.

Abstract

Almost all electrophysiology (EP) devices need to obtain premarket approval before they can be commercially sold and available for use in the community. The US Food and Drug Administration (FDA) has different paths to market approval depending on the intended use and the associated risks of the device. The European Union and Japan have device approval processes that have many similarities as well as differences to the US regulatory system. This paper describes some of the history and background of the US device approval process with an emphasis on EP devices. It provides an overview of the different regulatory pathways in the USA that are currently being utilized and contrasts them to the procedures often used in the European Union and in Japan. It also touches on the impact of the twenty-first Century Cures Act and how the balance between premarket and postmarket regulatory oversight is continually being examined and refined.

Keywords: Approval; De novo; Device; FDA; Premarket; Regulation.

Publication types

  • Review

MeSH terms

  • Cardiac Electrophysiology / instrumentation*
  • Device Approval*
  • Equipment Safety
  • European Union
  • Humans
  • Japan
  • Product Surveillance, Postmarketing
  • United States
  • United States Food and Drug Administration